EDP Announces Single Injection of New Insulin Maintains Tight Glucose Control for 140 Days

Results appearing in new issue of PNAS

DARIEN, Conn.--(BUSINESS WIRE)--Jul 13, 2010 - Extended Delivery Pharmaceuticals, LLC (EDP) announces that data regarding its lead development candidate SIA-II Insulin will be published in the new issue of Proceedings of the National Academy of Sciences of the USA. The manuscript describes multiple studies in vivo, in several species, demonstrating that a single injection of SIA-II maintains tight glucose control for over 140 days. SIA-II (Supramolecular insulin assembly -II) is a novel form of insulin.

“This may well be the single most important development in the management of diabetes during the last several years,” says James M. Fiore President and CEO of EDP.

SIA-II has been developed by the well-known glyco-biologist Professor Avadhesha Surolia, Director of the National Institute of Immunology in New Delhi, India (NII). Professor Surolia, who is the senior author of the manuscript said, “My colleagues and I are thrilled at the un-expected physico-chemical properties of this novel form of insulin. We look forward to its clinical development for the benefit of science and advancement of medicine.”

The published manuscript lists a number of unique properties of SIA-II, which distinguish it from known forms of insulin. In addition to maintaining tight control over blood glucose levels, SIA-II was shown to prevent end organ damage, and no episodes of hypoglycemia were observed. Additional studies are scheduled to begin shortly in a prestigious academic diabetes center in the United States.

Extended Delivery Pharmaceuticals, www.extendeddelivery.com, holds a world-wide exclusive license to SIA-II, from the National Institute of Immunology in New Delhi, India (NII).

Contact: Extended Delivery Pharmaceuticals
James M. Fiore, 203-656-2500
President & CEO
jfiore@extendeddelivery.com

 

Posted: July 2010

View comments

Hide
(web1)